key: cord-0710614-ggwjjuuf
authors: Arrigo, Serena; Alvisi, Patrizia; Banzato, Claudia; Bramuzzo, Matteo; Civitelli, Fortunata; Corsello, Antonio; D'Arcangelo, Giulia; Lillo, Anna Di; Dipasquale, Valeria; Felici, Enrico; Fuoti, Maurizio; Gatti, Simona; Giusti, Zeno; Knafeltz, Daniela; Lionetti, Paolo; Mario, Federica; Marseglia, Antonio; Martelossi, Stefano; Moretti, Chiara; Norsa, Lorenzo; Nuti, Federica; Panceri, Roberto; Rampado, Stefania; Renzo, Sara; Romano, Claudio; Romeo, Erminia; Strisciuglio, Caterina; Martinelli, Massimo
title: Management of paediatric IBD after the peak of COVID-19 pandemic in Italy: a position paper on behalf of the SIGENP IBD Working Group
date: 2020-10-22
journal: Dig Liver Dis
DOI: 10.1016/j.dld.2020.10.024
sha: 1b353267f070c78138f92469da9727d1bc24d6e3
doc_id: 710614
cord_uid: ggwjjuuf

Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2, spreading in Italy during the first months of 2020, abruptly changed the way of practicing medicine in this country. As a consequence of the lockdown, the diagnostic and therapeutic management of paediatric chronic conditions, such as inflammatory bowel disease (IBD) has been affected. During the peak of COVID-19 pandemic, elective visits, endoscopies and infusions have been postponed, with potential clinical and psychological impact on disease course and a high likelihood of increasing waiting lists. While slowly moving back towards normality, clinicians need to recognize the best ways to care for patients with IBD, carefully avoiding risk factors for new potential epidemic outbreaks. In this uncertain scenario until the development and spread of COVID-19 vaccine, it is necessary to continue to operate with caution. Hereby we provide useful indications for a safer and gradual restarting of routine clinical activities after COVID-19 peak in Italy.

Coronavirus Disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spreading in Italy during the first months of 2020, abruptly changed the way of practicing medicine in this country (1, 2) . The conversion of many hospitals into COVID-19 centres in highly affected regions, such as in Northern Italy, and the government lockdown have suddenly modified access to care for many patients (3) (4) (5) . Starting from March 9 th , all the national health system services had to postpone scheduled out and inpatients' visits, limiting the accesses to clinical urgencies. As a consequence, the diagnostic and therapeutic management of chronic inflammatory conditions, such as inflammatory bowel disease (IBD) has been significantly affected (6) (7) (8) .

Indeed, although IBD seems not to increase the risk of severe COVID-19 (9, 10) , its management requires endoscopic procedures, medical appraisal to monitor complications and hospital admission in case of severe flares. Furthermore, children with IBD are more commonly exposed to combined immunosuppressants and biologic therapies requiring accesses to the hospital for parenteral administrations. During COVID-19 peak, elective appointments and endoscopies have been postponed, with potential clinical and psychological impact on disease course and a high likelihood of increasing waiting lists (11, 12) . While slowly moving back towards normality, clinicians need to recognize the best ways to care for patients with IBD, carefully avoiding risk factors for new potential epidemic outbreaks (13) . In this uncertain scenario until the development and spread of COVID-19 vaccine, it is necessary to operate with caution. Therefore, the aims of this position paper are to provide guidance for the management of paediatric IBD on the basis of the existing evidences in the phases following the peak of the COVID-19 pandemic in order to ensure quality of care and avoid epidemic outbreaks.

A panel of 26 paediatric gastroenterologists and 2 psychologists (SR and ZG) with expertise in the field of paediatric IBD was selected in May 2020 following an open-call among the members of the Italian Society of Gastroenterology, Hepatology and Nutrition (SIGENP) IBD group study. The first webmeeting resulted in organising the position paper into 7 subparagraphs: 1) general considerations on hospital accesses; 2) diagnostic procedures 3) immunosuppressive therapies; 4) biologics; 5) telemedicine; 6) As previously outlined, COVID-19 outbreak forced a sudden general reorganization of hospital services and gastroenterology departments (3) (4) (5) . Paediatric IBD units experienced a global reduction in the number of hospitalizations, outpatient visits and routine endoscopies (11, 12) . Limiting as much as possible hospital admissions remains a crucial rule to prevent unnecessary exposure of IBD patients to the risk of SARS-CoV-2

infection. As suggested from An et al, the continuous assistance to many IBD patients can be ensured at home (14) . Patients with stable disease on maintenance therapy can be adequately followed in a scheduled program of telemedicine (15 Due to the supposed evidence of SARS-CoV-2 faecal-oral transmission digestive endoscopy is considered as an at risk procedure (18, 19) . Therefore, health institutions and major non-profit scientific societies recommended limiting endoscopic procedures in IBD patients to urgent indications, such as confirmation of new diagnoses, severe acute flare-ups in UC patients, or occurrence of complications (20, 21) . Selection and stratification of patients based on clinical symptoms, blood test results, non-invasive inflammatory markers, drug history and recent bowel surgery is strongly recommended (20, 21) . Whenever possible, and according to clinical indications, alternative disease assessment methods can be considered, including radiologic study, bowel ultrasound, magnetic resonance enterography, and indirect tools, such as faecal calprotectin (FC) (22) . On the other hand, performing bowel cleansing at home, can be taken into consideration based on patient age (≥10 years), compliance and family convenience.

Overall, endoscopy should not be deferred any further in case of: (i) mild-to-moderate flare-up with altered blood tests; (ii) symptoms of mild sub-acute obstruction already confirmed by a magnetic resonance or computed tomography scan, or bowel ultrasound;

(iii) new diagnosis; (iv) surveillance of post-operative recurrence within 1 year of surgery if the patient is symptomatic or FC and blood tests are worsening; (v) moderate pouchitis with symptoms and altered blood test results; (vi) endoscopic revaluation after 6 months of biological therapy in symptomatic patients with altered FC or blood tests (20, 21) . In all the other non-urgent procedures, the decision of postponing will be left to the caring physician on the basis of SARS-CoV2 spread and the limitation of each specific hospital setting.

Before performing the procedure, and preferably at hospital admission, all patients should undergo an epidemiological investigation. It is suggested to obtain naso-pharyngeal swab test for SARS-CoV-2 24-48 hours prior to all the procedures under deep sedation and/or general anaesthesia (20, 21) . Even after COVID-19 peak, especially in the high-risk areas, all endoscopy staff members, especially the operator, have to wear personal protective equipment (PPE) and frequently wash their hands with alcoholic solutions before and after procedures (Table 1 ) (23). It is still advisable to reduce the access and personnel density of endoscopy staff in the unit. Appointments for endoscopic procedures must be arranged to avoid crowding in the waiting room. Previous and successive cleaning of the equipment and of the operating room should always be ensured (20, 21) .

Recommendation: 

A placebo-controlled randomized trial showed that corticosteroids might reduce coronaviruses clearance (24) , whereas other studies suggested a possible positive influence of these drugs on coronavirus infections due to their anti-inflammatory properties (25) . Steroids are currently being used to treat patients with moderate-to-severe COVID-19 and to reduce the signs and symptoms of -super‖ inflammation in the later phases of the disease. However, in the early stages their use may increase viral burden. Recent uncontrolled study suggested that COVID-19 patients on high steroid dosage have significantly worse clinical outcomes than those without steroid use (26 Immunomodulators are commonly used in the management of IBD to maintain remission, as monotherapy or combination therapy with biologics. Most of these agents alter immune function by causing apoptosis of T cells (29) . Thiopurines (azathioprine, 6mercaptopurine) treatment can potentially reduce the number of activated T cells and

affect T-cell activation and effector function. Although no current data is available, thiopurines might affect the course of COVID-19 with lymphopenia being associated with a worse prognosis. Similarly, there is no specific data available on methotrexate (28) .

Therefore, in the absence of clear evidences we do not recommend the suspension of immunosuppressive treatment in patients with IBD. Moreover, although thiopurines may increase the risk of serious viral infections, the IOIBD does not recommend treatment discontinuation, taking into account the long washout period of these drugs (28) . In this setting the risk of a disease flare outweighs any estimated risk of SARS-CoV2 infection.

 The use of anti-TNFs should be continued at the regular intervals and doses.

[ The administration of biological drugs during COVID-19 epidemic peak has been an object of concern for patients and physicians in light of the possible infectious risks due to immunosuppression. Anti-TNFα antibodies may interfere with antiviral immunity directly by reducing TNFα levels and indirectly modulating T-lymphocyte activity and interferon-gamma production. However, the risk of increased susceptibility to viral infections and a complicated outcome conferred by anti-TNFα is controversial and strictly related to the specific pathogen (30) . On the other hand, the risks associated with the withdrawal of treatment for IBD must be taken into consideration. It has been reported that 21-23% of the children who delayed or temporarily discontinued infliximab infusions because of the epidemic, experienced a disease exacerbation (11) . To date, therapies targeting TNFα have not been associated with adverse outcomes in IBD patients with COVID-19 (27) Pre-infusion screening protocol to assess for acute respiratory tract symptoms and fever among IBD patients and their contacts should be performed.

The intravenous administration procedure of anti-TNFs should strictly follow measures to prevent any contaminations (7): There is no evidence to recommend RT-PCR/serological screening for SARS-CoV-2 in patients who need to start an anti-TNFα therapy (6, 7) . Asymptomatic patients with a reported close contact with infected subjects should undergo a screening with nasopharyngeal swab for SARS-CoV-2 before entering the gastroenterology unit or performing home therapy. Patients with symptoms compatible with COVID-19, regardless of contacts, should undergo a diagnostic naso-pharyngeal swab (6, 7) .

In this regard:

 Patients receiving hospital drug administration must go through the screening procedures described above.

 Patients under subcutaneous therapy must be instructed to promptly notify the caring physician of any symptoms related to COVID-19 and/or of any contacts with SARS-CoV-2 infected people.

 There is no evidence to support the suspension of biologic or In the last decade an important effort has been made to implement telemedicine in patients with IBD (37) . Randomized control trials conducted on cohorts of over 300 IBD adult patients demonstrated that telemedicine is a well-accepted method for delivering IBD consultation and it seems to increase patients' quality of life (QoL) and to decrease the rate of hospitalisations (38, 39) . Furthermore it has a great impact on costs for healthcare system and patients (40) . Regarding paediatric IBD the most interesting experience in telemedicine comes from Denmark. The web-application -young.constant-care.com‖ used in a randomized clinical trial in IBD children represents an appealing example of a telehealth system integrating measures of disease's activity, QoL, school attendance and compliance to treatment. The symptom score and FC level were combined into the total inflammation burden score. The intervention resulted in no differences between the 2 groups (eHealth vs standard care) in disease activity, treatment escalation, medical adherence and QoL (41) . Additionally, a significant reduction in the number of outpatient visits and IBD-related school absences was observed in the eHealth arm (41) . The same web system was successful used to individualize IFX infusions timing, with no significant development of IFX antibodies (42) . The recent outbreak of SARS CoV-2 has exposed paediatric gastroenterologists to a rapid change in daily practice (43) . Regarding followup, IBD experts and international societies recommended minimizing hospital admission by using telemedicine consultation (44) . In Italy,, several high volume IBD adult centres tried to change their practice in order to face this period with several difficulties (2, 4, 5) . In the paediatric age the only published experiences of telemedicine for IBD children during COVID-19 pandemic come from the United States (45, 46) .

Monitoring children with IBD through a telehealth system should include assessment of: 1) disease's activity and clinical status; 2) quality of life (QoL) and social/psychological issues; 3) adherence to treatment. Symptoms scores including the Pediatric Ulcerative

Colitis Activity Index (PUCAI) (47) and the non-invasive versions of the Pediatric Crohn's Disease Activity Index (PCDAI), including the abbreviated PCDAI (abbrPCDAI) and the short PCDAI (shPCDAI) (48) can be easily reported by patients not requiring blood tests (Table 2) . However, the lack of perfect agreement between patient and physician-based shPCDAI and PUCAI should be considered with children tending to score higher shPCDAI compared to physicians (49) , making a direct interview preferable. Furthermore, it is worth noticing that while PUCAI showed a good correlation with mucosal healing (MH) (50), none of the PCDAI versions can give a valid assessment of endoscopic healing (51) .

Along with symptoms recall it is also important to check a recent weight and height. FC, a non-invasive marker of MH (52), along with blood tests (blood count, ESR, CRP, albumin, liver function tests) can be requested at a local laboratory and results sent to the IBD centre. Home-based measurements of FC through lateral flow-based rapid tests are a promising option (53) . The self-reported IMPACT III questionnaire is a reliable instrument to investigate QoL in IBD children and adolescents, with a higher score representing a better QoL (54) ( Table 2) . No specific cut-off has been established to indicate an acceptable QoL, therefore longitudinal measures are suggested. School attendance and IBD related school absences, as indicators of general well being, are easily recorded by families, but are clearly not applicable in the pandemic era. A good adherence to medications is indicated from a score of or above 80% in the Medication Adherence Report Scale (MARS) that is a 5 point Likert scale (range 5-25 points) (55) or in the VAS line (a 10 cm long line indicating a spectrum from -always‖ to -never‖ taking medications) (56) . Patients tend to over-report the degree of adherence by using self-reported scales;

therefore, ideally, they should be accompanied by more objective measures such as pill count or blood level of the treatment drug (Table 2) .

The primary aim of telemedicine during COVID-19 pandemic is to provide patients and with a tele-health encounter has to be a shared between the provider, patient and family.

Lastly, the provider has to assure compliance to professional ethical principles, medical deontology and good professional practice rules.

We recommend restarting all the transition programmes, with the aid of telemedicine in order to limit hospital accesses in the high-risk area.

[ A successful transition from paediatric to adult IBD care is essential to maintain the continuity of care. The transition of care is a process rather than a single point in time, which has been extensively detailed (58, 59 Nevertheless the authors well emphasize the risk correlated to indefinitely postpone this crucial phase for IBD patients (60) . In the current emergency, telemedicine represents the ideal solution to keep transition programmes, ensuring the multidisciplinary involvement of different professionals and allowing the supervision of patients' skills trough the administration of specific questionnaires (61) . The visits and/or telephone contacts must take place involving contemporarily the paediatrician and the adult gastroenterologist.

Additionally the possibility of contact with the psychologist should be granted. This aspect underlines the importance to offer a support to the parents during this outbreak. Online consultations to parents seem to be useful to support them correctly communicating with their children. A good interaction between parents and children is one 

Facing Covid-19 in Italy -Ethics, Logistics, and Therapeutics on the Epidemic's Front Line

Challenges in the Care of IBD Patients During the CoViD-19 Pandemic: Report From a -Red Zone‖ Area in Northern Italy

Management of IBD during the COVID-19 outbreak: resetting clinical priorities

Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary

British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic

Inflammatory bowel disease management during the COVID-19 outbreak: a survey from the European Crohn's and Colitis Organization (ECCO)

) from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology, and Nutrition

Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study

Clinical and Psychological Issues in Children with Inflammatory Bowel Disease During COVID-19 Pandemic

Impact of COVID-19 on diagnosis and management of paediatric inflammatory bowel disease during lockdown: a UK nationwide study

Peyrin-Biroulet L. The day after COVID-19 in IBD: how to go back to 'normal

Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China

Feasibility and acceptance of a home telemanagement system in patients with inflammatory bowel disease: a 6-month pilot study

Telemedicine platform myIBDcoach reduces hospitalisations and outpatient gastroenterology visits in patients with IBD

ESGE and ESGENA Position Statement on gastrointestinal endoscopy and the COVID-19 pandemic

The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications

Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis

SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience

Recomendaciones de la SEED: Protecci n en Unidades de Endoscopia frente al COVID-19

Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition

Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients

Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry

COVID-19 and immunomodulation in IBD

Review article: prevention, diagnosis and management of COVID-19 in the IBD patient

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)

Pediatric Crohn's Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated with Infliximab

COVID-19 infection in Crohn's disease under treatment with adalimumab

novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases

Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial

Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases

Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting

Telemedicine in inflammatory bowel disease: opportunities and approaches

E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided ‗Constant-care' approach

A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD)

Delivering High Value Inflammatory Bowel Disease Care Through Telemedicine Visits

Self-managed eHealth Disease Monitoring in Children and Adolescents with Inflammatory Bowel Disease: A Randomized Controlled Trial

Individualized Infliximab Treatment Guided by Patient-managed eHealth in Children and Adolescents with Inflammatory Bowel Disease

Coronavirus Disease 2019 and the Pediatric Gastroenterologist

International Organization for the Study of Inflammatory Bowel Disease. Innovation in Inflammatory Bowel Disease Care During the COVID-19 Pandemic: Results of a Global Telemedicine Survey by the International Organization for the Study of Inflammatory Bowel Disease

COVID-19-A Guide to Rapid Implementation of Telehealth Services: A Playbook for the Pediatric Gastroenterologist

Telemedicine for Pediatric Inflammatory Bowel Disease in the Era of COVID-19

Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study

Mathematical weighting of the pediatric Crohn's disease activity index (PCDAI) and comparison with its other short versions

Do Children and Adolescents With Inflammatory Bowel Disease Complete Clinical Disease Indices Similar to Physicians

Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response

Which PCDAI Version Best Reflects Intestinal Inflammation in Pediatric Crohn Disease

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

Agreement Between Home-Based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity

The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease

Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease

Assessing Self-reported Medication Adherence in Inflammatory Bowel Disease: A Comparison of Tools

Spotlight on Transition in Patients With Inflammatory Bowel Disease: A Systematic Review

Successful Transition from Pediatric to Adult Care in Inflammatory Bowel Disease: What is the Key?

The management of inflammatory bowel diseases in the era of COVID-19 pandemic: When "non-urgent" does not mean "deferrable". Dig Liver Dis

Virtually Perfect? Telemedicine for Covid-19

Mitigate the effects of home confinement on children during the COVID-19 outbreak

Spotlight for healthy adolescents and adolescents with preexisting chronic diseases during the COVID-19 pandemic

Protecting the psychological health of children through effective communication about COVID-19